Search results
Author(s):
Yury Lopatin
Added:
3 years ago
In 2016, the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC)1 introduced heart failure (HF) with mid-range ejection fraction (HFmrEF) as a distinct phenotype. This distinction was expected to stimulate research on the underlying characteristics, pathophysiology and treatment of patients with HFmrEF. Indeed, in the following…
View more
Author(s):
Sunil K Nadar
,
Osama Tariq
Added:
3 years ago
The latest guidelines on the diagnosis and management of heart failure (HF) published by the European Society of Cardiology (ESC) introduced a new class of HF: HF with mid-range ejection fraction (HFmrEF).1 This was in addition to the previously-defined classes: HF with reduced ejection fraction (HFrEF), in which the left ventricular ejection fraction (LVEF) is below 40%, and HF with preserved…
View more
Author(s):
Lars H Lund
Added:
3 years ago
The cut-off values for “normal” ejection fraction (EF) are poorly defined. The EchoNoRMAL study suggested a lower boundary of 49–57%.1 The American Society of Echocardiography and European Association of Cardiovascular Imaging consider a normal EF and normal range (±2 SD) as 62% (52–72%) in men and 64% (54–74%) in women.2 By these criteria, an EF of 40–49% would not be considered normal.
However…
View more
Author(s):
Davide Margonato
,
Simone Mazzetti
,
Renata De Maria
,
et al
Added:
3 years ago
Heart failure (HF) is a complex syndrome caused by functional and structural abnormalities of the left ventricle (LV) resulting in a combination of typical signs and symptoms. Historically, HF has been classified according to LV ejection fraction (EF) as either HF with reduced EF (HFrEF; LVEF <40%) or HF with preserved EF (HFpEF; LVEF >50%).1,2 The 2016 European Society of Cardiology (ESC)…
View more
SGLT2 Inhibitors in HFpEF
Author(s):
Brent Deschaine
,
Sahil Verma
,
Hussein Rayatzadeh
Added:
1 year ago
Article
Author(s):
Antoni Bayés-Genís
,
Germán Cediel
,
Mar Domingo
,
et al
Added:
1 year ago
Author(s):
Otilia Țica
,
Waseem Khamboo
,
Dipak Kotecha
Added:
1 year ago
Author(s):
Martin Nicol
,
Mathilde Baudet
,
Alain Cohen-Solal
Added:
3 years ago
Advances in the early detection and treatment of cancer have improved overall survival in cancer patients. Nevertheless, cardiovascular diseases appear as the major cause of morbidity and mortality among cancer survivors.1 Left ventricular (LV) dysfunction and/or heart failure are the most common cardiovascular complications after administration of chemotherapies. The term ‘cardiotoxicity’ is…
View more
Author(s):
Veronika Zach
,
Felix Lucas Bähr
,
Frank Edelmann
Added:
4 years ago
Heart failure (HF) is a chronic, progressive disease with steadily increasing incidence rates and high morbidity and mortality that represents a major challenge in healthcare worldwide.1–3 The disease is characterised by chronic exacerbations, recurrent hospitalisations and poor prognosis.1,2 Survival rates in HF patients are lower than in patients suffering from some malignant diseases,…
View more
Author(s):
Andrew JS Coats
,
Louise G Shewan
Added:
3 years ago
What is Heart Failure?
Heart failure (HF) is a diagnosis made on clinical grounds, requiring at its simplest only a clinical history and physical examination findings, although, of course, certain investigations can help, especially imaging to assess left ventricular (LV) mechanical function. Unlike cancer, or even myocardial infarction (MI), there is no pathological or biochemical test that is…
View more